Uveitis – Pipeline Review, 2024

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

1.1. Report Overview

2. Uveitis - Overview

3. Executive Summary

4. Uveitis : PipelineAssessment

4.1. By Stage of Development

4.2. By Route of Administration

4.3. By Drug Class

4.4. By Molecule Type

4.5. By Therapy Area / Indication

4.6. By Drug Target

4.7. By Sponsor

5. Uveitis: Company& Drug Profiles

5.1. Clinical Stage

5.1.1.PP-001 – PANOPTES PHARMA GES.M.B.H

5.1.1.1.Company Overview

5.1.1.2.Product Description

5.1.1.3.R&D Status & Development Activities

5.1.1.4. Mechanism ofAction

5.1.1.5.Molecule Type

5.1.1.6.Stage of Development

5.1.1.7.Indications

5.1.1.8.Route of Administration

5.1.1.9.Funding

5.1.2.ADX-102 – Aldeyra Therapeutics

5.1.2.1.Company Overview

5.1.2.2.Product Description

5.1.2.3.R&D Status & Development Activities

5.1.2.4.Mechanism of Action

5.1.2.5.Molecule Type

5.1.2.6.Stage of Development

5.1.2.7.Indications

5.1.2.8. Route ofAdministration

5.1.2.9.Funding

5.1.3.CLS-TA – Clearside Biomedical, Inc.

5.1.3.1. CompanyOverview

5.1.3.2.Product Description

5.1.3.3.R&D Status & Development Activities

5.1.3.4.Mechanism of Action

5.1.3.5.Molecule Type

5.1.3.6. Stage ofDevelopment

5.1.3.7.Indications

5.1.3.8. Route ofAdministration

5.1.3.9.Funding

5.1.4.Others

5.2. Preclinical

5.2.1.Company Overview

5.2.2.Product Description

5.2.3.R&D Status & Development Activities

5.2.4.Mechanism of Action

5.2.5.Molecule Type

5.2.6.Indications

5.2.7.Route of Administration

5.2.8.Funding

6. Uveitis: AnOverview on Dormant & Discontinued Pipeline Candidates

6.1. Overview

6.2. Product Description

6.3. Reason for Discontinuation

7. Uveitis:Additional Key Insights

7.1. Epidemiology Overview: Uveitis

7.2. Current Market Scenario: Uveitis Therapeutics

8. Uveitis: News,Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.